ArriVent BioPharma (AVBP) Change in Account Payables (2023 - 2026)
ArriVent BioPharma (AVBP) posted Change in Account Payables of $2.8 million for Q1 2026, up 35187.5% sequentially from -$8000.0 in Q4 2025, and up 382.3% YoY from $582000.0 in Q1 2025.
ArriVent BioPharma (AVBP) Change in Account Payables (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Change in Account Payables for 4 years, with the latest figure at $2.8 million in Q1 2026.
- Quarterly Change in Account Payables rose 382.3% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 2029.76% YoY) and the FY2025 annual result came in at $2.1 million, up 385.09% from the prior year.
- Change in Account Payables advanced to $2.8 million in Q1 2026 per AVBP's latest filing, from -$8000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $3.7 million in Q2 2023 and troughed at -$2.2 million in Q3 2023.
- A 4-year average of $428923.1 and a median of -$8000.0 in 2025 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2024 and 2026: Change in Account Payables sank 393.22% in 2024, then soared 382.3% in 2026.
- Over 4 years, Change in Account Payables stood at $295000.0 in 2023, then tumbled by 393.22% to -$865000.0 in 2024, then soared by 99.08% to -$8000.0 in 2025, then jumped by 35187.5% to $2.8 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $2.8 million, -$8000.0, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | -6.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.51 Mn |
| Jun 30, 2026 | -6.51 Mn |
| Mar 31, 2026 | 2.81 Mn |
| Mar 31, 2026 | 2.81 Mn |
| Dec 31, 2025 | -8,000.00 |
| Dec 31, 2025 | -8,000.00 |
| Sep 30, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | -302,000.00 |
| Jun 30, 2025 | -302,000.00 |
| Mar 31, 2025 | 582,000.00 |
| Mar 31, 2025 | 582,000.00 |
| Dec 31, 2024 | -865,000.00 |
| Dec 31, 2024 | -865,000.00 |
| Sep 30, 2024 | 834,000.00 |
| Sep 30, 2024 | 834,000.00 |
| Jun 30, 2024 | -346,000.00 |
| Jun 30, 2024 | -346,000.00 |
| Mar 31, 2024 | -374,000.00 |
| Mar 31, 2024 | -374,000.00 |